Back

Find the FamiCord brand in your country

Free guide

Smart Cells free guide

Download

Transplant stories

Real Treatments. Real Families. Real Hope.

Smart Cells was the first private UK stem cell bank to release samples for transplant — proving that family cord blood banking is not just about storage, but about delivering real therapies when they are needed most.

Why Stem Cell Transplants Matter

At some point in life, your child or family member may need access to stem cell therapy. Today, these treatments are being used for:

  • Blood cancers such as leukaemia and lymphoma
  • Inherited genetic disorders including thalassemia and sickle cell disease
  • Neurological conditions such as cerebral palsy and brain injury
  • Immune deficiencies and metabolic disorders
  • Emerging therapies for sports injuries, inflammatory conditions, and skin repair

By preserving your baby’s umbilical cord blood and tissue, you safeguard access to these life-saving and life-enhancing possibilities.

Proven Track Record

Smart Cells has released more stem cell samples for treatment than any other private UK bank, with a 100% success rate for every sample delivered to clinicians worldwide.

These samples have helped children and families across the globe face illnesses such as:

  • Cerebral Palsy
  • Thalassemia
  • Leukaemia
  • HSV Encephalitis
  • Immune system disorders

Each transplant is more than a statistic — it represents a child given new options, and a family given hope.

A Milestone for Families and for Science

Every successful release shows how far the field of stem cell research has advanced. What was once only a possibility is now a proven therapy.

Yet many parents are still unaware of the benefits of storing their baby’s cord blood and tissue. Smart Cells is working to change that — by raising awareness, sharing real transplant stories, and supporting research into the next generation of regenerative treatments.

Powered by FamiCord: Europe’s Stem Cell Leader in banking and use of cells

As part of the FamiCord Group, Europe’s largest family stem cell bank and one of the world’s top three:

  • Families gain access to 1,000,000+ stored cord blood units across the network
  • Therapies are supported by specialist research centres and clinical teams in 35+ countries including FamiCord Programme for brain disorders
  • FamiCordTx, the group’s advanced therapies division, is actively developing new cell-based treatments to extend the possibilities for families everywhere

Together, Smart Cells and FamiCord stand at the forefront of innovation, offering parents confidence today — and hope for tomorrow.

FamiCord Group releases

Patients

7800+

Expand table
No. Source Source type Diagnosis Medical sector Year of application Therapy Country Age of the recipient
601 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 37
602 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 57
603 Apheresis Allogeneic Thalassemia Major Hematology 2026 Standard Therapy Turkey 1
604 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 59
605 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Switzerland 65
606 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 28
607 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Estonia 67
608 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Czechia 28
609 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Italy 71
610 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 73
611 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 73
612 Apheresis Allogeneic Acute Myeloblastic Leukemia Hematology 2026 Standard Therapy Romania 62
613 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 62
614 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy USA 52
615 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Italy 71
616 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Spain 48
617 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy USA 59
618 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 52
619 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 43
620 Apheresis Allogeneic Akut Myeloid Leukemia Hematology 2026 Standard Therapy Turkey 48
621 Apheresis Allogeneic Chronic myelomonocytic leukemia Hematology 2026 Standard Therapy Finland 16
622 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 30
623 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2026 Standard Therapy Germany 72
624 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 50
625 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 70
626 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Spain 45
627 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 75
628 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 39
629 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy USA 32
630 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Argentina 34
631 Apheresis Allogeneic Other Malignancy, Specify Hematology 2026 Standard Therapy USA 68
632 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Switzerland 63
633 Apheresis Allogeneic T-Cell Non-Hodgkin lymphoma Hematology 2026 Standard Therapy Argentina 70
634 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Czechia 52
635 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy France 62
636 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Italy 20
637 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 53
638 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy United Kingdom 56
639 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 71
640 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2026 Standard Therapy USA 54
641 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Hungary 36
642 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy France 47
643 Apheresis Autologus Diffuse Large B-Cell Lymphoma hematology 2026 Standard Therapy Germany 65
644 Apheresis Autologus Multiple Myeloma hematology 2026 Standard Therapy Germany 59
645 Apheresis Autologus Multiple Myeloma hematology 2026 Standard Therapy Germany 59
646 Apheresis Autologus Multiple Myeloma hematology 2026 Standard Therapy Germany 59
647 Apheresis Autologus Diffuse Large B-Cell Lymphoma hematology 2026 Standard Therapy Germany 63
648 Apheresis Autologus Multiple Myeloma hematology 2026 Standard Therapy Germany 37
649 Apheresis Autologus Multiple Myeloma hematology 2026 Standard Therapy Germany 61
650 Apheresis Autologus Multiple Myeloma hematology 2026 Standard Therapy Germany 63
651 Apheresis Allogeneic CMMOL-AML hematology 2026 Standard Therapy Hungary 47
652 Apheresis Allogeneic Acute Myelogenous Leukemia hematology 2026 Standard Therapy Spain 52
653 Apheresis Allogeneic Acute Myelogenous Leukemia hematology 2026 Standard Therapy Germany 53
654 Apheresis Allogeneic Myelodysplastic Syndrome hematology 2026 Standard Therapy Poland 61
655 Apheresis Allogeneic Other Non-Malignant Disease hematology 2026 Standard Therapy USA 67
656 Apheresis Allogeneic Myelodysplastic Syndrome hematology 2026 Standard Therapy Germany 3
657 Apheresis Allogeneic Acute Myelogenous Leukemia hematology 2026 Standard Therapy Germany 38
658 Apheresis Allogeneic Prolymphocytic Leukemia hematology 2026 Standard Therapy United Kingdom 60
659 Apheresis Allogeneic Acute Myelogenous Leukemia hematology 2026 Standard Therapy Poland 70
660 Apheresis Allogeneic Acute Myelogenous Leukemia hematology 2026 Standard Therapy Germany 48
661 Apheresis Allogeneic Acute Myelogenous Leukemia hematology 2026 Standard Therapy France 60
662 Apheresis Allogeneic Acute Myelogenous Leukemia hematology 2026 Standard Therapy USA 51
663 Apheresis Allogeneic Acute Myelogenous Leukemia hematology 2026 Standard Therapy Chile 6
664 Apheresis Allogeneic Acute Myelogenous Leukemia hematology 2026 Standard Therapy Germany 56
665 Apheresis Allogeneic Acute Myelogenous Leukemia hematology 2026 Standard Therapy USA 69
666 Apheresis Allogeneic Myelodysplastic Syndrome hematology 2026 Standard Therapy USA 41
667 Apheresis Allogeneic Chronic Myelomonocytic Leukemia hematology 2026 Standard Therapy United Kingdom 66
668 Apheresis Allogeneic Myelodysplastic Syndrome hematology 2026 Standard Therapy Italy 65
669 Apheresis Allogeneic Acute Lymphoblastic Leukemia hematology 2026 Standard Therapy Germany 49
670 Apheresis Allogeneic Acute Myelogenous Leukemia hematology 2026 Standard Therapy USA 76
671 Apheresis Allogeneic Acute Myelogenous Leukemia hematology 2026 Standard Therapy Italy 61
672 Apheresis Allogeneic Myelodysplastic Syndrome hematology 2026 Standard Therapy Poland 4
673 Apheresis Allogeneic Myelodysplastic Syndrome hematology 2026 Standard Therapy USA 65
674 Apheresis Allogeneic Acute Myelogenous Leukemia hematology 2026 Standard Therapy Poland 59
675 Apheresis Allogeneic Chronic Myelomonocytic Leukemia hematology 2026 Standard Therapy Germany 50
676 Apheresis Allogeneic Myelodysplastic/Myeloproliferative Neoplasms hematology 2026 Standard Therapy Poland 69
677 Apheresis Allogeneic Hodgkin Lymphoma hematology 2026 Standard Therapy USA 48
678 Apheresis Allogeneic Prolymphocytic Leukemia hematology 2026 Standard Therapy USA 71
679 Apheresis Allogeneic Acute Myelogenous Leukemia hematology 2026 Standard Therapy United Kingdom 55
680 Apheresis Allogeneic Acute Myelogenous Leukemia hematology 2026 Standard Therapy Germany 59
681 Apheresis Allogeneic Myelodysplastic Syndrome hematology 2026 Standard Therapy United Kingdom 62
682 Apheresis Allogeneic Acute Myelogenous Leukemia hematology 2026 Standard Therapy France 65
683 Apheresis Allogeneic Myelodysplastic Syndrome hematology 2026 Standard Therapy Germany 75
684 Apheresis Allogeneic Acute Myelogenous Leukemia hematology 2026 Standard Therapy Germany 57
685 Apheresis Allogeneic Acute Myelogenous Leukemia hematology 2026 Standard Therapy Germany 72
686 Apheresis Allogeneic Acute Myelogenous Leukemia hematology 2026 Standard Therapy Germany 32
687 Apheresis Allogeneic Acute Myelogenous Leukemia hematology 2026 Standard Therapy Bulgaria 63
688 Apheresis Allogeneic Myelofibrosis hematology 2026 Standard Therapy Hungary 52
689 Apheresis Allogeneic Myelodysplastic Syndrome hematology 2026 Standard Therapy Germany 64
690 Apheresis Allogeneic Non-Hodgkin Lymphoma hematology 2026 Standard Therapy Poland 24
691 Apheresis Allogeneic Acute Myelogenous Leukemia hematology 2026 Standard Therapy Germany 59
692 Apheresis Allogeneic Non-Hodgkin Lymphoma hematology 2026 Standard Therapy Belgium 65
693 Apheresis Allogeneic Chronic Myelomonocytic Leukemia hematology 2026 Standard Therapy USA 65
694 Apheresis Allogeneic Acute Lymphoblastic Leukemia hematology 2026 Standard Therapy USA 47
695 Apheresis Allogeneic Acute Myelogenous Leukemia hematology 2026 Standard Therapy Sweden 21
696 Apheresis Autologous Multiple Myeloma hematology 2026 Standard Therapy Portugal 57
697 Apheresis Autologous Multiple Myeloma hematology 2026 Standard Therapy Portugal 68
698 Cord Tissue Allogeneic – Related Chronic renal disease Endocrinology 2025 Experimental Therapy Romania 50
699 Cord Tissue Allogeneic – Related Autism Neurology 2025 Experimental Therapy Romania 6
700 Cord Tissue Autologous Autism Neurology 2025 Experimental Therapy Romania 6
Expand table

Stem cell transplantation has become an established procedure

700,000

cord blood collections have been undertaken globally

50,000

hematopoietic stem cell transplants take place every year

400/500

of these transplants are in Europe

Our transplant stories

Smart Cells have released 24 UK
samples to six countries.

Stem cells hold the key to more than 80 life-changing treatments, with clinical trials underway on many more. Replacing damaged cells and tissue, they can even save a child’s life.

Icon

100% infusion success rate

For samples released for transplant.

Icon

3 months – 12 yrs old

Stored cord blood samples have been successfully released for use in transplant for children aged as little as 3 months to 12 years old.

Icon

46% self | 54% siblings

Smart Cells have successfully released stored cord blood samples that have been used for treatment with the child it was collected from and also siblings.

Smart Cells releases

UK samples released

24

Expand table
Sample release date Medical condition Recipient relationship Age of the recipient Unit volume Medical center Country
2005.11 Thalassemia Allogeneic (Sibling) 4 Years 144ml Mount Vernon Hospital Singapore
2005.11 Leukaemia Allogeneic (Sibling) Restricted Restricted Stem Cells and Immunology Department, Birmingham UK
2007.02 Thalassemia Allogeneic (Sibling) 7 Years 76ml Kinderlink der Tu Munchen Germany
2009.08 Cerebral Palsy Autologous (Self) 3 Years 51ml Duke University, North Carolina USA
2010.01 Cerebral Palsy Autologous (Self) 3 Years 81ml Duke University, North Carolina USA
2013.10 Thalassemia Allogeneic (Sibling) 5 Years 58ml Catherine Lewis Centre, Hammersmith UK
2014.01 Leukaemia Allogeneic (Sibling) 4 Years 71ml Medizinische Hochschule, Hanover Germany
2014.05 Cerebral Palsy Autologous (Self) 1 year 68ml Duke University, North Carolina USA
2014.06 HSV Encephalitis & NMDA Receptor Antibody Virus Autologous (Self) 2 Years 57ml Duke University, North Carolina USA
2014.08 Hypoxic Ischemic Encephalopathy (HIE) Autologous (Self) 3 Months 39ml Duke University, North Carolina USA
2015.02 Hypoxic Ischemic Encephalopathy (HIE) Autologous (Self) 6 Months 53ml Duke University, North Carolina USA
2015.03 Severe Combined Immune Deficiency Autologous (Self) 3 Months 74ml Duke University, North Carolina USA
2015.03 Sickle Cell Disease Allogeneic (Sibling) 2 .5 Years 57ml BLK Hospital, New Delhi India
2015.11 Thalassemia Allogeneic (Sibling) 12 Years 87ml Children’s Hospital of Pittsburgh of UPMC USA
2016.03 Cerebral Palsy Allogeneic (Sibling) 6 Years 101ml Duke University, North Carolina USA
2017.04 Lymphoblastic Leukaemia (^1) N/A (Identical twin girls) Restricted 125ml Bambin Gesu Childrens’ Hospital, Rome Italy
2017.06 Cerebral Palsy Autologous (Self) 7 Years 82ml Duke University, North Carolina USA
2017.06 Cerebral Palsy Autologous (Self) 3.4 Years 132ml Duke University, North Carolina USA
2018.03 Autism Autologous (Self) 5.4 Years 73ml Duke University, North Carolina USA
2018.03 Cerebral Palsy Autologous (Self) 3.4 years 132ml Duke University, North Carolina USA
2019.06 Cerebral Palsy Allogeneic (Sibling) 3 Years 104ml Duke University, North Carolina USA
2022.02 Cerebral Palsy Allogeneic (Sibling) 11 Years 185ml Duke University, North Carolina USA
2023.08 Cerebral Palsy Allogeneic (Sibling) 3 Years 46ml Duke University, North Carolina USA
2024.01 Thalassaemia Allogeneic (Sibling) 8 Years 45ml Cincinnati Children’s Hospital Medical Center USA
Expand table
Icon

Ready to get started or need more information?